Authored by: Ms Chandra Ganjoo, Group Chief Executive Officer, Trivitron Healthcare
The medical device sector is composed of transformative changes as we move into 2024. With advancements in technology and evolving market dynamics, the industry is experiencing significant shifts towards automation, AI driven solutions, next-generation sequencing, digital therapeutics, and biometric devices, and impact on various medical specialties such as orthopedics, cardiology, and urology.
Digital therapeutics, software-based medical devices, gained prominence during the pandemic. These AI-driven tools enable clinicians to diagnose, manage, and treat diseases virtually, enhancing care efficiency and accessibility. According to Frost & Sullivan by 2025, the U.S. market for digital therapeutics is projected to grow at a compound annual growth rate (CAGR) of 29.8%. At-home diagnostics, which empower patients to conduct self-tests, also surged during the pandemic. The in-vitro diagnostic market, although slowed post-pandemic, demonstrated the potential for self-tests in diagnosing various health conditions, expanding consumer markets, and improving healthcare access.
Wearable and biometric technologies is also on favorable growth trajectory, with the global market for wearable tech expected to reach $161 billion by 2033, growing at a CAGR of 6%. Popular devices, alongside specialized sensors such as electrocardiogram (ECG) and photoplethysmogram (PPG), empower consumers to manage their health. The healthcare sectors leading wearable tech adoption include audiology, kinesiology, and occupational therapy. Innovations in generative AI (genAI) and alternative data investments are further accelerating growth in this space.
Next-generation sequencing and genomics are revolutionizing the medical device industry by enabling unprecedented precision in diagnostics and personalized medicine. NGS technologies allow for the rapid sequencing of entire genomes, providing detailed insights into genetic variations and their health implications. This advancement is particularly transformative in areas like oncology, where it enables the identification of specific genetic mutations that drive cancer, allowing for tailored treatment strategies. Additionally, NGS is crucial in infectious disease control, aiding in the rapid identification of pathogens and their resistance profiles, thus informing effective therapeutic interventions.
The surge in demand for weight loss medications raised concerns about their impact on medical device companies, particularly those involved in bariatric surgery. Despite potential threats, analysts remain optimistic due to issues like high costs, limited accessibility, and side effects of weight loss drugs. Data suggests patients are unlikely to use these drugs long-term, indicating a continued need for medical device treatments.
Speed to market is critical in the competitive medical device industry. Companies are adopting strategies such as technology reuse, focusing on core competencies, outsourcing, managing strategic partnerships, and standardizing systems. These approaches enhance regulatory and validation processes, operational efficiencies, and innovation, enabling faster market entry without compromising safety and quality.
The medical device industry is shifting towards greater inclusivity, recognizing the diverse needs of global populations. Now, companies are tailoring solutions to various demographics, addressing language barriers, cultural differences, and unique market conditions in developing nations.
As healthcare industry is responsible for over 4.6% of global greenhouse gas emissions, as sustainability is a persistent concern. MedTech companies are under pressure to reduce environmental impact through practices like reprocessing devices, which can cut hospital costs by up to 50% and ozone depletion by almost 90%. Environmental, Social and Governance initiatives are becoming integral, with 80% of medical device companies planning to adjust operations to address sustainability, according to an EY survey.
Generative AI (genAI) is revolutionizing the medtech industry by improving manufacturing and distribution efficiency. It also enables medical devices to diagnose and recommend treatments, reducing hospital costs and improving patient outcomes. However, rigorous regulatory oversight is essential to ensure safe deployment.
The medtech industry is on a rapid growth path, with in-vitro diagnostics (IVD) expected to remain the top segment in 2024. Neurology is projected to be the fastest-growing device specialty, while cardiology, diagnostic imaging, orthopedics, and diabetes care are among the top areas by sales. Despite regulatory challenges, companies that embrace sustainability, digital transformation, and AI technologies will lead the industry, improving global healthcare outcomes.
